Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued Access Protocol for Drisapersen in DMD
NCT01890798Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Jan 2014
- Primary completion
- Jan 2014
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
01
Overview
A Phase 3 trial of drisapersen in Duchenne muscular dystrophy (DMD), sponsored by GSK. Planned start Jan 2014; status: withdrawn.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01890798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01890798.